Search research articles
Contact Us
Filters
Showing results (101-110 of 143) with videos related to
Page
of 15
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 17, 2007
Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study
Rochelle Bagatell, Lia Gore, Merrill J Egorin, et al.
Cancer Chemotherapy and Pharmacology
|
April 17, 2008
Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine
Smitha S Krishnamurthi, Joanna M Brell, Charles L Hoppel, et al.
Investigational New Drugs
|
July 18, 2013
A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors
Ivan Diaz-Padilla, Hal Hirte, Amit M Oza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2008
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group
Ramesh K Ramanathan, Merrill J Egorin, Chris H M Takimoto, et al.
Molecular Cancer Therapeutics
|
February 13, 2023
A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE)
Elizabeth Pan, Wanling Xie, Archana Ajmera, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 27, 2022
Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma
James Nguyen, Naoko Takebe, Shivaani Kummar, et al.
Investigational New Drugs
|
May 3, 2014
A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients
Anna Spreafico, Kim N Chi, Srikala S Sridhar, et al.
Investigational New Drugs
|
August 1, 2012
A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors
Amir Mortazavi, Yonghua Ling, Ludmila Katherine Martin, et al.
Breast Cancer Research and Treatment
|
February 28, 2023
A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620)
Monica K Malhotra, Shalu Pahuja, Brian F Kiesel, et al.
NPJ Precision Oncology
|
December 5, 2017
Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival
Ovidiu C Andronesi, Morteza Esmaeili, Ronald J H Borra, et al.
Page
of 15
Search research articles
Search
Showing results (101-110 of 143) with videos related to
Sort By:
Page
of 15
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 17, 2007
Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study
Rochelle Bagatell, Lia Gore, Merrill J Egorin, et al.
Cancer Chemotherapy and Pharmacology
|
April 17, 2008
Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine
Smitha S Krishnamurthi, Joanna M Brell, Charles L Hoppel, et al.
Investigational New Drugs
|
July 18, 2013
A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors
Ivan Diaz-Padilla, Hal Hirte, Amit M Oza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2008
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group
Ramesh K Ramanathan, Merrill J Egorin, Chris H M Takimoto, et al.
Molecular Cancer Therapeutics
|
February 13, 2023
A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE)
Elizabeth Pan, Wanling Xie, Archana Ajmera, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 27, 2022
Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma
James Nguyen, Naoko Takebe, Shivaani Kummar, et al.
Investigational New Drugs
|
May 3, 2014
A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients
Anna Spreafico, Kim N Chi, Srikala S Sridhar, et al.
Investigational New Drugs
|
August 1, 2012
A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors
Amir Mortazavi, Yonghua Ling, Ludmila Katherine Martin, et al.
Breast Cancer Research and Treatment
|
February 28, 2023
A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620)
Monica K Malhotra, Shalu Pahuja, Brian F Kiesel, et al.
NPJ Precision Oncology
|
December 5, 2017
Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival
Ovidiu C Andronesi, Morteza Esmaeili, Ronald J H Borra, et al.
Page
of 15